Amicus Therapeutics Inc - Company Profile
Powered by 
All the sales intelligence you need on Amicus Therapeutics Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Amicus Therapeutics Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Amicus Therapeutics Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Amicus Therapeutics Inc (Amicus Therapeutics) is a biotechnology company. It focuses on the research, development, and commercialization of small molecule drugs. These drugs, known as pharmacological chaperones, are orally administered for the treatment of rare and orphan diseases. The company offers Galafold (migalastat), a small molecule that is indicated for the treatment of Fabry disease; and Pombiliti and Opfolda, for the treatment of Pompe disease in adults. DMX-200 is a small molecule inhibitor of the chemokine receptor 2 (CCR2) under development in a pivotal Phase 3 study (ACTION3), for the treatment of FSGS kidney disease. The company has a presence in the US, the UK, Switzerland, Italy, Ireland, Germany, Spain, and Japan. Amicus Therapeutics is headquartered in Princeton, New Jersey, the US.
Headquarters
United States of America
Address
47 Hulfish Street, Princeton, New Jersey, 08542
Website
www.amicusrx.com
Telephone
1 609 6622000
No of Employees
511
Industry
Pharmaceuticals and Healthcare
Revenue (2025)
$634.2M
Amicus Therapeutics Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| - | Galafold |
| Galafold (migalastat) HCl - Fabry Disease | Pombiliti |
| Pombiliti + Opfolda - Pompe Disease | Opfolda |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Ownership Changes | In April, the company was acquired by BioMarin Pharmaceutical Inc for US$4.8 billion. |
| 2024 | Contracts/Agreements | In October, the company entered into an agreement with Teva Pharmaceuticals USA, Inc. and Teva Pharmaceuticals, Inc. to resolve patent litigation related to Teva’s new drug application for a generic version of GALAFOLD (migalastat) 123 mg capsules before the patents expire. |
| 2023 | Financing Agreements | In October, the company entered into an agreement for US$430 million financing collaboration with funds managed by Blackstone. |
Competitor Comparison
| Key Parameters | Amicus Therapeutics Inc | Bayer AG | Takeda Pharmaceutical Co Ltd | Vertex Pharmaceuticals Inc | Chiesi Farmaceutici SpA |
|---|---|---|---|---|---|
| Headquarters | United States of America | Germany | Japan | United States of America | Italy |
| City | Princeton | Leverkusen | Chuo-Ku | Boston | Parma |
| State/Province | New Jersey | Nordrhein-Westfalen | Tokyo | Massachusetts | Emilia-Romagna |
| No. of Employees | 511 | 92,815 | 47,455 | 6,400 | 7,686 |
| Entity Type | Private | Public | Public | Public | Private |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Michael G. Raab | Chairman | Executive Board | 2024 | 61 |
| Bradley L. Campbell | Chief Executive Officer; Director; President | Executive Board | 2022 | 50 |
| Simon Harford | Chief Financial Officer | Senior Management | 2023 | 65 |
| Ellen S. Rosenberg | Chief Legal Officer | Senior Management | 2019 | 63 |
| David M. Clark | Chief People Officer | Senior Management | 2018 | 51 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer